English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the zaia usage as premium feature

ZAIA

Presents the pdf analysis as premium feature

PDF Analysis

Insights

Presents the summarisation as premium feature

Summarisation

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the access of premium content as premium feature

Premium Content

Zendy Tools

Zendy Open

Background  Venous thromboembolism ( VTE ) is a serious complication in patients with lung cancer. The benefit of chemotherapy for lung cancer patients with  VTE  remains unknown. This study was conducted to elucidate the efficacy and safety of chemotherapy for advanced non‐small cell lung cancer ( NSCLC ) in patients with  VTE .    Methods  Newly diagnosed patients with advanced (i.e. stage  IIIB  and  IV )  NSCLC  with  VTE  who received systemic chemotherapy were studied. Response rates, progression‐free survival ( PFS ), overall survival ( OS ), and toxicity were retrospectively analyzed.    Results   I n this study, 21 patients who received chemotherapy plus anticoagulation therapy between  D ecember 2009 and  F ebruary 2011 were included. The objective response and disease control rates within the first regimen were 14.29% (3/21) and 76.19 %(16/21), respectively. The median  PFS , one‐year survival rate, and median  OS  were 5.50 months, 33.30%, and 8.70 months, respectively. The main grade 3/4 toxicities observed included neutropenia (28.57%), nausea 4 (19.05%), and anemia 2 (9.52%). Major bleeding was not observed.    Conclusion  Chemotherapy for newly diagnosed patients with advanced  NSCLC  and  VTE  was feasible and had acceptable toxicity; however, the survival of these patients remained inferior to that of patients without  VTE .

Efficacy and safety of chemotherapy for newly diagnosed advanced non‐small cell lung cancer with venous thromboembolism